Spiegel, Jay Y. http://orcid.org/0000-0001-6491-0044
Patel, Shabnum http://orcid.org/0000-0002-4782-9540
Muffly, Lori http://orcid.org/0000-0002-9887-6136
Hossain, Nasheed M. http://orcid.org/0000-0002-3278-655X
Oak, Jean
Baird, John H. http://orcid.org/0000-0001-8291-6546
Frank, Matthew J.
Shiraz, Parveen
Sahaf, Bita
Craig, Juliana http://orcid.org/0000-0002-5644-2292
Iglesias, Maria
Younes, Sheren
Natkunam, Yasodha http://orcid.org/0000-0002-9816-1018
Ozawa, Michael G.
Yang, Eric
Tamaresis, John
Chinnasamy, Harshini
Ehlinger, Zach
Reynolds, Warren
Lynn, Rachel
Rotiroti, Maria Caterina
Gkitsas, Nikolaos
Arai, Sally
Johnston, Laura
Lowsky, Robert
Majzner, Robbie G. http://orcid.org/0000-0001-6969-8011
Meyer, Everett
Negrin, Robert S.
Rezvani, Andrew R.
Sidana, Surbhi http://orcid.org/0000-0003-3288-7614
Shizuru, Judith http://orcid.org/0000-0003-3246-4726
Weng, Wen-Kai
Mullins, Chelsea
Jacob, Allison
Kirsch, Ilan
Bazzano, Magali
Zhou, Jing
Mackay, Sean
Bornheimer, Scott J.
Schultz, Liora
Ramakrishna, Sneha http://orcid.org/0000-0001-7445-3190
Davis, Kara L. http://orcid.org/0000-0002-7182-2592
Kong, Katherine A.
Shah, Nirali N. http://orcid.org/0000-0002-8474-9080
Qin, Haiying http://orcid.org/0000-0001-5966-8812
Fry, Terry http://orcid.org/0000-0001-8044-5226
Feldman, Steven
Mackall, Crystal L. http://orcid.org/0000-0001-6323-4304
Miklos, David B. http://orcid.org/0000-0003-0717-4305
Article History
Received: 29 September 2020
Accepted: 9 June 2021
First Online: 26 July 2021
Competing interests
: C.L.M. is an inventor on a patent application for CD19/22-CAR T cells and holds several patent applications in the area of CAR T cell immunotherapy. C.L.M. is a founder of, holds equity in and receives consulting fees from Lyell Immunopharma and Syncopation Life Sciences. She has also received consulting fees from NeoImmune Tech, Nektar Therapeutics, Immatics, GlaxoSmithKline and Apricity Health and royalties from Juno Therapeutics for the CD22-CAR. She holds equity in Vor Biopharma and Apricity Health. D.B.M. has consulted for Kite-Gilead, Juno Therapeutics-Celgene-Bristol Myers Squibb, Novartis and Adaptive Biotechnologies. He has received research for Kite-Gilead and Adaptive Biotechnologies. S.F. has consulted for Lonza PerMed, Gradalis, Obsidian and Samsara Biocapital. L.M. has consulted for Amgen, Pfizer and Kite-Gilead. She has received research funding from Adaptive Biotechnologies, Astellas Pharma, Servier and Baxalta. S.P. has consulted for Cellares. R.S.N. has consulted for Kuur Therapeutics, who are developing CAR invariant NKT cells, and CoImmune, who are developing CAR cytokine-induced killer cells. A.R.R. has received research support from Pharmacyclics and performed a one-time ad hoc scientific advisory board role for Nohla and Koledio. He is a medical expert witness for the U.S. Department of Justice; his brother works for Johnson & Johnson. H.Q. is an inventor on a patent application for CD19/22-CAR T cells and holds several patent applications in the area of CAR T cell immunotherapy. She has also received royalties from Lentigen via the NIH for the thymic stromal lymphopoietin receptor-CARs. I.K., C.M. and A.J. are full-time employees and shareholders of Adaptive Biotechnologies. R.G.M. holds several patent applications in the area of CAR T cell immunotherapy and is a consultant for Lyell Immunopharma, Xyphos Biosciences, GammaDelta Therapeutics, Zai Lab and Aptorum Group. The other authors declare no conflicts of interest.